Investors & Media
Press Releases
2022
-
- October 27, 2022
-
Anokion Announces Leadership Team Expansion to Support Advancement of Clinical-Stage Autoimmune Pipeline
Read More
-
- October 21, 2022
-
Anokion Announces Presentation of Data from Phase 1 ACeD Clinical Trial Evaluating KAN-101 as a Treatment for Celiac Disease at the 19th International Celiac Disease Symposium
Read More
-
- October 18, 2022
-
Anokion Announces $35 Million Equity Investment from Pfizer
Read More
-
- May 23, 2022
-
Anokion Announces Positive Data from Phase 1 ACeD Clinical Trial Evaluating KAN-101 as a Treatment for Celiac Disease Presented in a Plenary Session at DDW 2022
Read More
-
- January 06, 2022
-
Anokion Announces Progress Across Pipeline of Novel Autoimmune Programs
Read More